A hip fracture causes bleeding, pain and immobility, and initiates inflammatory, hypercoagulable, catabolic and stress states in patients. Accelerated surgery may improve outcomes by reducing the duration of these states and immobility.

The objective of the HIP ATTACK-1 trial is to determine the effect of accelerated medical clearance and accelerated surgery compared to standard care on the 90-day risk of the following two co-primary outcomes: all-cause mortality and major perioperative complications.

Primary outcome measures:

1) All-cause mortality; and

2) composite of major perioperative complications:

i.e., mortality, nonfatal myocardial infarction, nonfatal venous thromboembolism, nonfatal pneumonia, nonfatal sepsis, nonfatal stroke, nonfatal life-threatening bleeding, and major bleeding) at 90 days after randomization.

Mohit Bhandari is Co-Principal Investigator of the HIP ATTACK-1 trial, along with PJ Devereaux.

HIP ATTACK Slides - Download PDF
Study Type

Interventional - Procedure

Study Design

Multicentre, parallel group RCT

NO. of Countries


NO. of Sites


NO. of Participants


Study Period

2014 - 2020



Mohit Bhandri interviews PJ Devereaux about their HIP ATTACK Trial

VIDEO: Mohit Bhandari interviews co-PI PJ Devereaux about HIP ATTACK

VIDEO: Flavia Borges on Methods Behind HIP ATTACK

Canadian Institutes of Health Research (CIHR)

Ontario SPOR Support Unit (OSSU)

Back To Top